Stanford team regrows joint cartilage by blocking an 'ageing' enzyme

Scientists at Stanford Medicine have reported a way to regrow lost joint cartilage and head off arthritis in mice, a finding that could eventually offer an alternative to the surgery many people with worn-out joints currently face. The work was published in the journal Science.

At the centre of the research is an enzyme called 15-PGDH, which the team describes as acting like a biological brake on the body's natural ability to regenerate cartilage. Levels of the enzyme roughly doubled with age in the cartilage of the mice studied, and blocking it with a small-molecule inhibitor appeared to release that brake.

If the approach holds up in people, it would represent a meaningful shift in how a stubborn, common condition is treated. Cartilage has long been considered notoriously poor at healing itself, which is why damaged joints tend to deteriorate over time rather than recover. A therapy that coaxes the tissue back into a regenerative state would challenge that assumption.

The notion that ageing tissue retains a latent capacity to repair, held in check by a single molecular brake, is part of what makes the finding exciting to researchers. It suggests that some of the decline associated with growing older may be driven by specific, identifiable signals rather than by an irreversible loss of regenerative potential, and that those signals might one day be adjusted.

Restored joints and a human tissue test

Older mice given the inhibitor showed restored cartilage thickness and improved joint function, while animals treated after an ACL-style injury were far less likely to go on to develop osteoarthritis than untreated controls. Encouragingly, human tissue samples taken during knee-replacement operations also began producing new, functional cartilage when exposed to the treatment within a week.

That combination of results matters. Demonstrating an effect in ageing animals addresses the wear-and-tear form of the disease that most people develop slowly over decades. Showing that the same intervention can prevent arthritis after an injury speaks to a different group of patients entirely, including younger people whose joints are damaged in sport or accidents.

The early signal in human tissue is perhaps the most intriguing element. While laboratory samples are a long way from a living, weight-bearing joint, the fact that discarded human cartilage responded at all suggests the underlying biology may translate across species rather than being a quirk of mouse physiology.

Why the stakes are so high

The stakes are significant. Osteoarthritis affects roughly one in five adults in the United States and is estimated to generate around 65 billion US dollars in healthcare costs each year. An oral pill or local injection that rebuilds cartilage could, in principle, spare many patients invasive joint-replacement surgery.

Current options for advanced joint disease are limited and largely palliative. Patients typically cycle through painkillers, physiotherapy and steroid injections before eventually facing a knee or hip replacement, a major operation that carries its own risks and a finite lifespan for the implant. None of these approaches restore the underlying tissue; they manage symptoms or replace the joint outright.

A regenerative treatment would change that calculus in several ways:

• Potentially delaying or avoiding joint-replacement surgery altogether
• Offering an option for younger patients for whom implants are less ideal
• Treating the cause of joint degradation rather than just masking pain
• Reducing the long-term healthcare costs associated with chronic arthritis
• Targeting both age-related wear and post-injury disease

“This is a new way of regenerating adult tissue, and it has significant clinical promise.”

— Professor Helen Blau, Stanford Medicine

Background: a hard problem in regenerative medicine

Researchers have spent years trying to make cartilage heal, with mixed results from cell transplants, scaffolds and growth factors. The appeal of the Stanford approach is its relative simplicity: rather than implanting new material, it aims to switch a single enzyme back towards a more youthful balance, allowing the body to do the repair work itself. The use of a small-molecule inhibitor also raises the prospect of a drug that could be taken as a pill or delivered by injection, rather than a complex surgical procedure.

The same enzyme, 15-PGDH, has been studied in other contexts, including muscle ageing, which has helped researchers understand how to target it safely. That existing body of work could, in theory, smooth the path towards human trials, though regulators will want to see careful evidence that switching off the enzyme does not cause unwanted effects elsewhere in the body.

“The leap from a promising mouse study to an approved medicine is where most candidates fail. Encouraging biology is necessary, but it is only the first step.”

— Regenerative-medicine researcher

What happens next

As with all early-stage research, the leap from mice and laboratory tissue to a proven human therapy remains long and uncertain. The next milestones will be rigorous safety testing and, eventually, carefully designed clinical trials in patients. The Stanford team's results nonetheless mark an intriguing step towards treating a condition that has long been managed rather than reversed, and they add to a growing sense that the body's own repair machinery can sometimes be coaxed back to life.